Related Experiment Videos
[Clinical experience with T-1982 (cefbuperazone) in the pediatric field]
Insights
Cefbuperazone (T-1982) effectively treated acute bacterial infections in 20 of 21 pediatric patients. This antibiotic demonstrated clinical efficacy with minimal side effects, suggesting its utility in pediatric infectious disease management.
Area of Science:
- Pediatric infectious diseases
- Bacteriology
- Pharmacology
Background:
- Acute bacterial infections pose a significant health concern in pediatric populations.
- The need for effective and safe antibiotic treatments in children is critical.
Purpose of the Study:
- To evaluate the clinical and bacteriological effectiveness of cefbuperazone (T-1982) in treating acute bacterial infections in children.
- To assess the safety and side effect profile of cefbuperazone in this pediatric cohort.
Main Methods:
- Intravenous administration of cefbuperazone (T-1982) to 21 pediatric patients.
- Inclusion of diverse acute bacterial infections: bronchopneumonia, urinary tract infections, abscesses, lymphadenitis, tonsillitis, and bronchitis.
- Monitoring of clinical outcomes and bacteriological eradication.
Main Results:
- High clinical effectiveness observed in 20 out of 21 cases (95.2%).
- Bacteriological effectiveness was achieved in 7 out of 8 evaluable cases (87.5%).
- A single case of asymptomatic eosinophilia was the only noted side effect, with no other laboratory abnormalities.
Conclusions:
- Cefbuperazone (T-1982) demonstrates significant clinical and bacteriological efficacy in treating various acute bacterial infections in pediatric patients.
- The antibiotic exhibits a favorable safety profile, with minimal adverse effects observed.
- Cefbuperazone is a promising therapeutic option for pediatric infectious disease management.
Abstract:
T-1982 (cefbuperazone) was given intravenously to 21 children with the following acute bacterial infections; 13 cases of bronchopneumonia, 2 cases of urinary tract infection, 1 case of subcutaneous abscess, 1 case of cervical purulent lymphadenitis and acute tonsillitis, and 4 cases of acute bronchitis. Clinical effectiveness was obtained in 20 cases out of 21 cases and bacteriological effectiveness in 7 cases out of 8 cases. As for the side effects, 1 patient had asymptomatic eosinophilia, but no other laboratory abnormalities were observed. Above results suggest that T-1982 is a useful antibiotic for treating pediatric patients with various kinds of bacterial infections.